UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

Journal of clinical oncology, 2020-07, Vol.38 (21), p.2369-2379

2020

Volltextzugriff (PDF)

Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199

Journal of clinical oncology, 2014-10, Vol.32 (29), p.3275-3283

2014

Volltextzugriff (PDF)

Reply to J.-G. Wang et al

Journal of clinical oncology, 2021-09, Vol.39 (27), p.3088-3089

2021

Volltextzugriff (PDF)

Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline

Journal of clinical oncology, 2024-02, Vol.42 (5), p.584-604

2024

Volltextzugriff (PDF)

Revised risk classification for pediatric extracranial germ cell tumors based on 25 years of clinical trial data from the United Kingdom and United States

Journal of clinical oncology, 2015-01, Vol.33 (2), p.195-201

2015

Volltextzugriff (PDF)

Surveillance After Initial Surgery for Pediatric and Adolescent Girls With Stage I Ovarian Germ Cell Tumors: Report From the Children's Oncology Group

Journal of clinical oncology, 2014-02, Vol.32 (5), p.465-470

2014

Volltextzugriff (PDF)

Improvement of Overall and Failure-Free Survival in Stage IV Follicular Lymphoma: 25 Years of Treatment Experience at The University of Texas M.D. Anderson Cancer Center

Journal of clinical oncology, 2006-04, Vol.24 (10), p.1582-1589

2006

Volltextzugriff (PDF)

Treatment of Childhood Nasopharyngeal Carcinoma With Induction Chemotherapy and Concurrent Chemoradiotherapy: Results of the Children's Oncology Group ARAR0331 Study

Journal of clinical oncology, 2019-12, Vol.37 (35), p.3369-3376

2019

Volltextzugriff (PDF)

Treatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children's Oncology Group ARAR0332 Protocol

Journal of clinical oncology, 2021-08, Vol.39 (22), p.2463-2473

2021

Volltextzugriff (PDF)

Real-world (RW) characteristics, treatment patterns, and outcomes of patients with cholangiocarcinoma (CCA) treated with pemigatinib

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.444-444

2024

Volltextzugriff (PDF)

Cisplatin-induced nephrotoxicity in hyperthermic intraperitoneal chemotherapy (HIPEC) is mitigated by sodium thiosulfate: Clinical and toxicotranscriptomic results of a prospective trial

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.5570-5570

2022

Volltextzugriff (PDF)

Safety and clinical activity of MEDI5752, a PD-1/CTLA-4 bispecific checkpoint inhibitor, as monotherapy in patients (pts) with advanced renal cell carcinoma (RCC): Preliminary results from an FTIH trial

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.107-107

2022

Volltextzugriff (PDF)

A randomized, double-blind, phase 3 trial of MK-7684A plus chemotherapy versus pembrolizumab plus chemotherapy as first-line therapy for metastatic non–small cell lung cancer (NSCLC): KeyVibe-007

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS9160-TPS9160

2022

Volltextzugriff (PDF)

Whole transcriptome changes correlate to exceptional ovarian cancer responders: A sub-analysis of a HIPEC Phase I trial

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.6060-6060

2020

Volltextzugriff (PDF)

Intensive Multimodality Therapy for Extraocular Retinoblastoma: A Children's Oncology Group Trial (ARET0321)

Journal of clinical oncology, 2022-11, Vol.40 (33), p.3839-3847

2022

Volltextzugriff (PDF)

Feasibility of collaborative precision medicine oncology between academic- and community-based hospitals

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e18015-e18015

2017

Volltextzugriff (PDF)

Infrequent Tumor Initiative of the Children's Oncology Group: Initial Lessons Learned and Their Impact on Future Plans

Journal of clinical oncology, 2010-11, Vol.28 (33), p.5011-5016

2010

Volltextzugriff (PDF)

Carcinomas in the children and young adults: A report form Children’s Oncology Group APEC14B1 study

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e21505-e21505

2019

Volltextzugriff (PDF)

Characterization of Pulmonary Metastases in Children With Hepatoblastoma Treated on Children's Oncology Group Protocol AHEP0731 (The Treatment of Children With All Stages of Hepatoblastoma): A Report From the Children's Oncology Group

Journal of clinical oncology, 2017-10, Vol.35 (30), p.3465-3473

2017

Volltextzugriff (PDF)

Small Cell Undifferentiated Histology Does Not Adversely Affect Outcome in Hepatoblastoma: A Report From the Children's Oncology Group (COG) AHEP0731 Study Committee

Journal of clinical oncology, 2022-02, Vol.40 (5), p.459-467

2022

Volltextzugriff (PDF)

VERU-111, an oral cytoskeleton disruptor, to treat men with metastatic castration-resistant prostate cancer (mCRPC) who failed an androgen receptor targeting agent

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.5056-5056

2021

Volltextzugriff (PDF)

Infigratinib versus placebo in patients with resected urothelial cancer (UC) bearing FGFR3 mutation or fusion: Primary DFS analysis from the phase 3, randomized PROOF302 study

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.629-629

2024

Volltextzugriff (PDF)

Final analysis of the phase 1b/2 study of sabizabulin in men with metastatic castration-resistant prostate cancer who progressed on an androgen receptor targeting agent

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.5049-5049

2022

Volltextzugriff (PDF)

The role of sabizabulin in phase 1b/2 clinical trials of men with metastatic castration-resistant prostate cancer who progressed on androgen receptor-targeting agents

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.110-110

2022

Volltextzugriff (PDF)

1 – 25 von 94

Suche als RSS-Feed

Aktive Filter

KollektionSpringerLink (Online service)

Zeitschrift / SerieJournal Of Clinical Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(94)
Mit Volltextzugriff
(91)

Publikationsform

Artikel
(94)

Sprache

Englisch
(94)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

Humans
(21)
Oncology
(21)
Life Sciences & Biomedicine
(20)
Science & Technology
(20)
Female
(18)
Male
(13)
Adolescent
(11)
Child
(11)
Original Reports
(10)
Adult
(9)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(9)
Child, Preschool
(7)
Disease-Free Survival
(7)
Middle Aged
(7)
Neoplasm Staging
(7)
Aged
(6)
Biological And Medical Sciences
(6)
Medical Sciences
(6)
Cisplatin - Administration & Dosage
(5)
Infant
(5)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

1 weiteren anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199

Reply to J.-G. Wang et al

Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline

Revised risk classification for pediatric extracranial germ cell tumors based on 25 years of clinical trial data from the United Kingdom and United States

Surveillance After Initial Surgery for Pediatric and Adolescent Girls With Stage I Ovarian Germ Cell Tumors: Report From the Children's Oncology Group

Improvement of Overall and Failure-Free Survival in Stage IV Follicular Lymphoma: 25 Years of Treatment Experience at The University of Texas M.D. Anderson Cancer Center

Treatment of Childhood Nasopharyngeal Carcinoma With Induction Chemotherapy and Concurrent Chemoradiotherapy: Results of the Children's Oncology Group ARAR0331 Study

Treatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children's Oncology Group ARAR0332 Protocol

Real-world (RW) characteristics, treatment patterns, and outcomes of patients with cholangiocarcinoma (CCA) treated with pemigatinib

Cisplatin-induced nephrotoxicity in hyperthermic intraperitoneal chemotherapy (HIPEC) is mitigated by sodium thiosulfate: Clinical and toxicotranscriptomic results of a prospective trial

Safety and clinical activity of MEDI5752, a PD-1/CTLA-4 bispecific checkpoint inhibitor, as monotherapy in patients (pts) with advanced renal cell carcinoma (RCC): Preliminary results from an FTIH trial

A randomized, double-blind, phase 3 trial of MK-7684A plus chemotherapy versus pembrolizumab plus chemotherapy as first-line therapy for metastatic non–small cell lung cancer (NSCLC): KeyVibe-007

Whole transcriptome changes correlate to exceptional ovarian cancer responders: A sub-analysis of a HIPEC Phase I trial

Intensive Multimodality Therapy for Extraocular Retinoblastoma: A Children's Oncology Group Trial (ARET0321)

SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer

Feasibility of collaborative precision medicine oncology between academic- and community-based hospitals

Infrequent Tumor Initiative of the Children's Oncology Group: Initial Lessons Learned and Their Impact on Future Plans

Carcinomas in the children and young adults: A report form Children’s Oncology Group APEC14B1 study

Characterization of Pulmonary Metastases in Children With Hepatoblastoma Treated on Children's Oncology Group Protocol AHEP0731 (The Treatment of Children With All Stages of Hepatoblastoma): A Report From the Children's Oncology Group

Small Cell Undifferentiated Histology Does Not Adversely Affect Outcome in Hepatoblastoma: A Report From the Children's Oncology Group (COG) AHEP0731 Study Committee

VERU-111, an oral cytoskeleton disruptor, to treat men with metastatic castration-resistant prostate cancer (mCRPC) who failed an androgen receptor targeting agent

Infigratinib versus placebo in patients with resected urothelial cancer (UC) bearing FGFR3 mutation or fusion: Primary DFS analysis from the phase 3, randomized PROOF302 study

Final analysis of the phase 1b/2 study of sabizabulin in men with metastatic castration-resistant prostate cancer who progressed on an androgen receptor targeting agent

The role of sabizabulin in phase 1b/2 clinical trials of men with metastatic castration-resistant prostate cancer who progressed on androgen receptor-targeting agents

Aktive Filter

Suchergebnisse filtern